CTOs on the Move

Biomatrix

www.biomatrix.com

 
Biomatrix, Inc., together with its subsidiaries in Canada, Europe and Asia, develops, manufactures, markets and sells a series of proprietary viscoelastic products called hylans that are used in therapeutic medical applications and skin care. Hylans are
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Clinical Technology Inc

Clinical Technology Inc is a Broadview Heights, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Instromedix dba: LifeWatch

Instromedix dba: LifeWatch is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

xiqi biomedical instrument co.,ltd

xiqi biomedical instrument co.,ltd is a Taizhou, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evofem Biosciences

Evofem, Inc. is a privately held biotechnology company that discovers, develops and commercializes prescription and over-the-counter products in the areas of feminine care, contraception, and the prevention of sexually transmitted infections. Evofem, Inc. is committed to delivering effective, woman-controlled, rapidly reversible forms of contraception to women globally. In February 2013, Evofem entered into a strategic alliance with Woman Care Global, a nonprofit organization whose mission is to provide access to quality, affordable, women`s healthcare products through a sustainable value chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, Woman Care Global provides sales, marketing and global distribution support to Evofem`s products.

GT Medical Technologies

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.